Summary
We have investigated whether the pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride are altered with proteinuria by studying 8 patients with major proteinuria of different causes who were given a single dose of 10 mg p.o.
The maximum plasma concentration of benazepril was found between 0.5 and 2 h after dosing (median 1 h). Its elimination was almost complete within 6 h. Peak plasma levels of benazeprilat, the active metabolite of benazepril, were observed between 1 and 6 h (median 2.5 h). The elimination of benazeprilat from plasma was biphasic, with mean initial and terminal half-lives of 3.0 and 17.3 h, respectively. On average, the pharmacokinetic parameters of benazepril and benazeprilat in the patients did not differ from those in a historical control group of healthy volunteers, but intersubject variability in the AUC and half-lives of benazeprilat was greater in the patients.
Plasma ACE was completely inhibited from 1.5 to 6 h after dosing, and at 48 h the mean inhibition was still 42 %. Plasma renin showed substantial intersubject variation. Mean supine blood pressure (systolic/diastolic) was reduced from baseline by a maximum of 18/13 mm Hg at 6 h. Proteinuria was diminished after benazepril in 7 patients.
In conclusion, the results of this study suggest that proteinuria in the nephrotic range does not require a change in benazepril dosage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D (1987) Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 32: 78–83
Parving HH, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 297: 1086–1091
Björck S, Mulec H, Johnsen SA, Nyberg G, Aurell M (1990) Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. Br Med J 300: 904–907
Götz R, Drechsler U, Heidbreder E, Heidland A (1988) Einfluß des Angiotensin-Konversionsenyzm-Inhibitors Ramipril auf Proteinurie, Blutdruck und Nierenfunktion bei histologisch gesicherten Glomerulonephritiden mit nephrotischem Syndrom. Z Kardiol 77 [Suppl 3]: 65–68
Balfour JA, Goa KL (1991) Benazepril. A review of its pharmacodynamic and pharmocokinetic properties and therapeutic efficacy in hypertension and congestive heart failure. Drugs 42: 511–539
Kaiser G, Ackermann R, Brechbühler S, Dieterle W (1989) Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. Biopharm Drug Dispos 10: 365–376
Kaiser G, Ackermann R, Sioufi A (1989) Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special population. Am Heart J 117: 746–751
Kaiser G, Ackermann R, Dieterle W, Durnin CJ, McEwen J, Ghose K, Richens A, Holmes IB (1990) Pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol 38: 379–385
Kaiser G, Ackermann R, Gschwind HP, James IM, Sprengers D, McIntyre N, DeFalco A, Holmes IB (1990) The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride. Biopharm Drug Dispos 11: 753–764
Sioufi A, Pommier F, Gauducheau N, Godbillon J, Bodin F, Darragon T (1992) Pharmacokinetics of benazepril and benazeprilat in hypertensive patients with renal impairment during one year treatment with daily doses of 10 mg of benazepril hydrochloride. J Pharm Clin (Special Issue: Pharmacocinétique: de la recherche à la clinique): 330–340
Waldmeier F, Kaiser G, Ackermann R, Faigle JW, Wagner J, Barner A, Lasseter KC (1991) The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. Xenobiotica 21: 251–261
Gugler R and Azarnoff DL (1976) Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet 1: 25–35
Haldimann B, Healy M, Jelliffe R, Goldstein DA, Pattabhiraman R, Massry SG (1980) Effect of an oral dose of 25-hydroxyvitamin D3 on its blood levels in patients with the nephrotic syndrome. J Clin Endocrinol Metab 50: 470–474
Bazzato G, Coli U, Landini S, Fracasso A, Righetto F, Scanferla F, Forte M, Morachiello P (1985) Muzolimine vs. furosemide in nephrotic syndrome: further support of different carrier(s) operating for enteral absorption. Z Kardiol 74 [Suppl 2]: 92–95
Sioufi A, Pommier F, Kaiser G, Dubois JP (1988) Determination of benazepril, a new angiotensin-converting enzyme inhibitor, and its active metabolite, benazeprilat, in plasma and urine by capillary gas chromatography-mass selective detection. J Chromatogr 434: 239–246
Cushman DW, Cheung HS (1971) Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20: 1637–1648
Lieberman J (1975) Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med 59: 365–372
Ménard J, Guyenne TT, Corvol P, Pau B, Simon D, Roncucci R (1985) Direct immunometric assay of active renin in human plasma. J Hypertension 3 [Suppl 3]: S275-S278
Kukovetz WR, Kaiser G, Ackermann R, Barner A (1992) Effects of food on the pharmacokinetics, safety, and tolerability of benazepril hydrochloride. Today's Therapeutic Trends 10 [Suppl 1]: 3–14
Bakris GL (1990) Effects of diltiazem or lisionpril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112: 707–708
Valentino VA, Wilson MD, Weart W, Bakris GL (1991) A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med 151: 2367–2372
Stornello M, Valvo EV, Scapellato L (1992) Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and β-adrenoceptor blockers. Clin Sci 82: 19–23
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schweizer, C., Kaiser, G., Dieterle, W. et al. Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria. Eur J Clin Pharmacol 44, 463–466 (1993). https://doi.org/10.1007/BF00315544
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315544